登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C23H32N2O5
化学文摘社编号:
分子量:
416.51
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
MDL number:
InChI
1S/C23H32N2O5/c1-3-30-23(29)18(13-12-16-8-5-4-6-9-16)24-15(2)21(26)25-19-11-7-10-17(19)14-20(25)22(27)28/h4-6,8-9,15,17-20,24H,3,7,10-14H2,1-2H3,(H,27,28)/t15-,17-,18-,19-,20-/m0/s1
SMILES string
O=C(N1[C@](CCC2)([H])[C@]2([H])C[C@H]1C(O)=O)[C@H](C)N[C@H](C(OCC)=O)CCC3=CC=CC=C3
InChI key
HDACQVRGBOVJII-JBDAPHQKSA-N
grade
pharmaceutical primary standard
API family
ramipril
manufacturer/tradename
USP
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
2-8°C
Gene Information
human ... ACE(1636)
正在寻找类似产品? 访问 产品对比指南
Analysis Note
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
Biochem/physiol Actions
Angiotensin converting enzyme (ACE) inhibitor.
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Other Notes
Sales restrictions may apply.
signalword
Danger
hcodes
存储类别
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
flash_point_f
Not applicable
flash_point_c
Not applicable
Hazard Classifications
Repr. 1A
W Linz et al.
Zeitschrift fur Kardiologie, 83 Suppl 4, 53-56 (1994-01-01)
ACE inhibitors induce an increase in kinin levels with subsequent release of nitric oxide (NO) and prostacyclin, as shown in cultured endothelial cells and isolated rat hearts. Isolated perfused working rat hearts continuously release kinins and prostacyclin. During ischemia after
Carolina De Ciuceis et al.
Hypertension (Dallas, Tex. : 1979), 64(4), 717-724 (2014-07-02)
Structural alterations of subcutaneous small-resistance arteries are associated with a worse clinical prognosis in hypertension and non-insulin-dependent diabetes mellitus. The effects of the direct renin inhibitor aliskiren on microvascular structure were never previously evaluated. Therefore, we investigated the effects of
April D Vuong et al.
The Annals of pharmacotherapy, 37(3), 412-419 (2003-03-18)
To evaluate the effectiveness of ramipril in the prevention and treatment of cardiovascular disease and determine its need for inclusion on a formulary. A MEDLINE and PubMed database search was conducted (1987-May 2002). Only journals written in the English language
J E Frampton et al.
Drugs, 49(3), 440-466 (1995-03-01)
Ramipril is a second generation angiotensin converting enzyme (ACE) inhibitor. Like enalapril, it is a prodrug and is hydrolysed in vivo to release the active metabolite, ramiprilat, which has a long elimination half-life, permitting once-daily administration. The antihypertensive efficacy of
W H Smith et al.
International journal of clinical practice, 54(4), 255-260 (2000-07-27)
Ramipril is a long-acting, lipophylic angiotensin converting enzyme inhibitor, its principle action is to inhibit the conversion of angiotensin I to the active angiotensin II. Ramipril is indicated in the treatment of hypertension, congestive cardiac failure (including that following acute
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持